Yan DL - Search Results

1

MiR-31 inhibits migration and invasion by targeting SATB2 in triple negative breast cancer.

Luo LJ, Yang F, Ding JJ, Yan DL, Wang DD, Yang SJ, Ding L, Li J, Chen D, Ma R, Wu JZ, Tang JH. Luo LJ, et al. Among authors: yan dl. Gene. 2016 Dec 5;594(1):47-58. doi: 10.1016/j.gene.2016.08.057. Epub 2016 Sep 1. Gene. 2016. PMID: 27593563

2

Liver X receptor as a drug target for the treatment of breast cancer.

Wu Y, Yu DD, Yan DL, Hu Y, Chen D, Liu Y, Zhang HD, Yu SR, Cao HX, Feng JF. Wu Y, et al. Among authors: yan dl. Anticancer Drugs. 2016 Jun;27(5):373-82. doi: 10.1097/CAD.0000000000000348. Anticancer Drugs. 2016. PMID: 26872310 Review.

3

Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.

Sha HH, Wang DD, Yan DL, Hu Y, Yang SJ, Liu SW, Feng JF. Sha HH, et al. Among authors: yan dl. Biosci Rep. 2017 Jan 27;37(1):BSR20160332. doi: 10.1042/BSR20160332. Print 2017 Feb 28. Biosci Rep. 2017. PMID: 28053197 Free PMC article. Review.

4

Elevated serum levels of vascular endothelial growth factor predict a poor prognosis of platinum-based chemotherapy in non-small cell lung cancer.

Zang J, Hu Y, Xu X, Ni J, Yan D, Liu S, He J, Xue J, Wu J, Feng J. Zang J, et al. Onco Targets Ther. 2017 Jan 18;10:409-415. doi: 10.2147/OTT.S124124. eCollection 2017. Onco Targets Ther. 2017. PMID: 28176920 Free PMC article.

5

Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.

Hu Y, Zang J, Cao H, Wu Y, Yan D, Qin X, Zhou L, Fan F, Ni J, Xu X, Sha H, Liu S, Yu S, Wang Z, Ma R, Wu J, Feng J. Hu Y, et al. Oncotarget. 2017 Feb 28;8(9):15802-15814. doi: 10.18632/oncotarget.15007. Oncotarget. 2017. PMID: 28178657 Free PMC article.

6

Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.

Hu Y, Qin X, Yan D, Cao H, Zhou L, Fan F, Zang J, Ni J, Xu X, Sha H, Liu S, Yu S, Wu J, Ma R, Feng J. Hu Y, et al. Tumour Biol. 2017 Mar;39(3):1010428317691659. doi: 10.1177/1010428317691659. Tumour Biol. 2017. PMID: 28345454 Free article.

7

MiR-138: A promising therapeutic target for cancer.

Sha HH, Wang DD, Chen D, Liu SW, Wang Z, Yan DL, Dong SC, Feng JF. Sha HH, et al. Among authors: yan dl. Tumour Biol. 2017 Apr;39(4):1010428317697575. doi: 10.1177/1010428317697575. Tumour Biol. 2017. PMID: 28378633 Free article. Review.

8

Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin.

Hu Y, Zang J, Qin X, Yan D, Cao H, Zhou L, Ni J, Yu S, Wu J, Feng JF. Hu Y, et al. Onco Targets Ther. 2017 Apr 28;10:2341-2348. doi: 10.2147/OTT.S124757. eCollection 2017. Onco Targets Ther. 2017. PMID: 28496332 Free PMC article.

9

DNA methylation mediated silencing of microRNA-874 is a promising diagnosis and prognostic marker in breast cancer.

Zhang L, Yan DL, Yang F, Wang DD, Chen X, Wu JZ, Tang JH, Xia WJ. Zhang L, et al. Among authors: yan dl. Oncotarget. 2017 Jul 11;8(28):45496-45505. doi: 10.18632/oncotarget.17569. Oncotarget. 2017. PMID: 28525377 Free PMC article.

10

Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.

Qin X, Yu S, Zhou L, Shi M, Hu Y, Xu X, Shen B, Liu S, Yan D, Feng J. Qin X, et al. Int J Nanomedicine. 2017 May 15;12:3721-3733. doi: 10.2147/IJN.S131516. eCollection 2017. Int J Nanomedicine. 2017. PMID: 28553110 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

48 results

Search Page

Filters